Entrada (TRDA): Rasio rega marang pendapatan

Tandha merek Entrada Therapeutics Inc. (TRDA)

Unique patent protection for its intracellular delivery platform shields Entrada Therapeutics (TRDA) from price competition. The price-to-sales multiple filters out market noise, while the 50.80 mark reflects the current valuation. The financial success of Entrada Therapeutics (TRDA) relies on future sales of Duchenne muscular dystrophy treatments. Its status as a scientific pioneer in brain and muscle therapy strengthens the confidence of the global community.

TRDA Multiplikator P/S Entrada Therapeutics (21.05.2023 - 13.11.2026)

Rincian analitis perusahaan Entrada (TRDA)

- kuotasi saiki lan rata-rata prakiraan nilai:
Rega bursa entradatx.com|TRDA - Bagan rega target
- data kapitalisasi bursa:
Nilai pasar Entrada|TRDA - Nilai Total Perusahaan
- statistik nilai buku emiten:
Nilai Aset Bersih saben Saham Entrada Therapeutics|TRDA - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas entradatx.com|TRDA - Gunggung Aset Perusahaan
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Entrada Therapeutics|TRDA - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Entrada Therapeutics, Inc|TRDA - Utang perusahaan|Rasio utang marang nilai buku Entrada|TRDA - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Entrada Therapeutics|Rasio jangkoan perantara entradatx.com
- data bathi lan kelipatan valuasi:
TRDA - Bathi resik|Proyeksi bathi mangsa ngarep Entrada Therapeutics|TRDA - Pangali P/E|Rasio rega marang bathi mangsa ngarep Entrada Therapeutics Inc.|TRDA - Pangali PEG|Pangali EV/EBITDA Entrada|TRDA - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Entrada Therapeutics|TRDA - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan entradatx.com|TRDA - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Entrada Therapeutics
- rincian pendapatan lan dodolan emiten:
TRDA - Pendapatan lan volume dodolan|Volume dodolan sing dikarepake perusahaan entradatx.com|TRDA - Rasio rega marang pendapatan|Rega forward marang dodolan Entrada
Analisis fundamental perusahaan:entradatx.com (TRDA)
Produk seri Entrada Therapeutics, Inc.

The P/S ratio determines the market value of a business relative to its annual sales, allowing an investor to identify a fair valuation range and the risks of capital stagnation. By analyzing the calculated price-to-sales ratio, one can assess the capitalization efficiency of Entrada Therapeutics (TRDA), whose value is currently based on the potential of neuromuscular disease therapies and the costs of maintaining high-tech laboratories.

Karo sapa Entrada Therapeutics saingan

JAZZ - Rega marang dodolan|Rasio rega marang pendapatan Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Rasio rega marang pendapatan|SRRK - Rasio rega marang pendapatan|Rega marang dodolan Centessa Corp|DYN: Multiplikator P/S|Multiplikator rega marang pendapatan edgewisetx.com EWTX|Kapitalisasi marang pendapatan RAPP|Rega marang dodolan Alumis Inc ALMS|Multiplikator P/S ZVRA|CTNM - Rega marang dodolan|Rasio rega marang pendapatan Larimar Therapeutics LRMR|CAPR: Rasio kapitalisasi marang pendapatan|PTHS: Kapitalisasi marang pendapatan|MediciNova, Inc. - Kapitalisasi marang volume dodolan|Serina (SER) - Rasio rega marang pendapatan|BioXcel Therapeutics Corp - Rasio kapitalisasi pasar marang pendapatan|PMN (ProMIS Neurosciences Inc.) - Multiplikator P/S|Multiplikator P/S Apimeds|Multiplikator P/S AEON|nlspharma.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNOX (Bionomics)|Multiplikator P/S fsdpharma.com HUGE|RETA: Kapitalisasi marang pendapatan